In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator : Correlation with physico-chemical properties and oral activity
The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ ra...
Saved in:
Published in | Pharmaceutical research Vol. 16; no. 3; pp. 434 - 440 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Springer
01.03.1999
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described.
Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures.
Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals.
Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate. |
---|---|
AbstractList | The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described.
Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures.
Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals.
Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate. The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate. PURPOSEThe in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. METHODSCaco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. RESULTSCaco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. CONCLUSIONSCaco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate. |
Author | DONNELLY, H OBERLE, R FALLER, B HIRSCHBERG, Y LOWTHER, N FOX, R NICK, H SERGEJEW, T YI JIN |
Author_xml | – sequence: 1 givenname: N surname: LOWTHER fullname: LOWTHER, N organization: Pharmaceutical and Analytical Development, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom – sequence: 2 givenname: R surname: FOX fullname: FOX, R organization: Pharmaceutical and Analytical Development, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom – sequence: 3 givenname: B surname: FALLER fullname: FALLER, B organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland – sequence: 4 givenname: H surname: NICK fullname: NICK, H organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland – sequence: 5 surname: YI JIN fullname: YI JIN organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland – sequence: 6 givenname: T surname: SERGEJEW fullname: SERGEJEW, T organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland – sequence: 7 givenname: Y surname: HIRSCHBERG fullname: HIRSCHBERG, Y organization: Bioanalytics and Pharmacokinetics, Novartis Pharmaceuticals Corporation, Summit, New Jersey, United States – sequence: 8 givenname: R surname: OBERLE fullname: OBERLE, R organization: Bioanalytics and Pharmacokinetics, Novartis Pharmaceuticals Corporation, Summit, New Jersey, United States – sequence: 9 givenname: H surname: DONNELLY fullname: DONNELLY, H organization: Globepharm Ltd, P.O. Box 89C, Esher, Surrey KT10 9ND, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1738283$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10213376$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkE1rFTEUhoNU7G117U6CiF2NniQzmUx35eJHoeBGwd2QZM54U2aSMclU59_4U03rFcHV4cDznvPwnpETHzwS8pzBGwZcvL26ZMCUUhKgYUI-IjvWtKLqoP56QnbQ8rpSbc1OyVlKtwCgWFc_Iacly4Ro5Y78uvb0zuUYqPYDdZ4ml1e6YJxRGze5vNEwUk0vEtpQiG_oMersgr-gh22I4ee2bNEN7l6Mhqgn6mLw1B5w0jlEekn3Icb7pWToD5cPdDlsydlQFWZ2tiSWGMrH7DA9WDxc0Ta7IrY9JY9HPSV8dpzn5Mv7d5_3H6ubTx-u91c31cKlyJXgTDHeSWOVqREFNi2gFNYAGwDHWsLARhBSKNtIY4yQgMjBMADejDUX5-T1n7tF5vuKKfezSxanSXsMa-pl10LLlCjgy__A27BGX9x6zrnsFIe6QC-O0GpmHPolulnHrf9bfAFeHQGdSgVj1N669I9rheLl2W8gh5XI |
CODEN | PHREEB |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS Copyright Kluwer Academic Publishers Mar 1999 |
Copyright_xml | – notice: 1999 INIST-CNRS – notice: Copyright Kluwer Academic Publishers Mar 1999 |
DBID | IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1023/A:1018886005136 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest One Academic Eastern Edition MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1573-904X |
EndPage | 440 |
ExternalDocumentID | 520263981 10213376 1738283 |
Genre | Journal Article News |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 8W4 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFLS ABFTV ABHLI ABHQN ABIPD ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTHY ABTMW ABULA ABUWG ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOAH ADRFC ADTIX ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESTI AETLH AEVTX AEXYK AFDYV AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMYLF AMYQR AOSHJ ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBAFP BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG COF CS3 CSCUP DL5 DNIVK DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IJ- IMOTQ INH IPNFZ IQODW ITM IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH KSO L7B LAK LLZTM LSO M1P M4Y MA- MK0 N2Q N95 N9A NAPCQ NB0 NDZJH NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PQEST PQQKQ PQUKI PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNX SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 WOW YCJ YLTOR Z45 Z5O Z7S Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z84 Z87 Z88 Z8N Z8O Z8P Z8Q Z8R Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ~KM AACDK AAEOY AAJBT AAQLM AASML AATNV AAYZH ABAKF ABJNI ABTKH ABWNU ACAOD ACDTI ACZOJ ADTPH AEFQL AEMSY AESKC AEVLU AFBBN AGQEE AGRTI AIGIU ALIPV AMXSW AOCGG CCPQU CGR CUY CVF DDRTE DPUIP ECM EIF HMCUK IKXTQ IWAJR NPM NPVJJ SNPRN SOHCF 7TK 7XB 8FK K9. PRINS 7X8 |
ID | FETCH-LOGICAL-p263t-32181296bc8b4ee3e570e63cb01d0ef460d1f03638c56bbb360ee20b10025f423 |
IEDL.DBID | BENPR |
ISSN | 0724-8741 |
IngestDate | Fri Oct 25 08:26:48 EDT 2024 Thu Oct 10 18:47:48 EDT 2024 Wed Oct 16 00:50:10 EDT 2024 Fri Nov 25 06:01:31 EST 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Human Rat Digestive system Biological transport Rodentia Gut Solubility Oral administration Lipophily Iron Bioavailability Permeability In vitro In vivo Vertebrata Mammalia Absorption Animal Established cell line Chelating agent Pharmacokinetics Tumor cell Physicochemical properties |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-p263t-32181296bc8b4ee3e570e63cb01d0ef460d1f03638c56bbb360ee20b10025f423 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 10213376 |
PQID | 222698204 |
PQPubID | 37334 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_69707183 proquest_journals_222698204 pubmed_primary_10213376 pascalfrancis_primary_1738283 |
PublicationCentury | 1900 |
PublicationDate | 1999-03-01 |
PublicationDateYYYYMMDD | 1999-03-01 |
PublicationDate_xml | – month: 03 year: 1999 text: 1999-03-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States – name: New York |
PublicationTitle | Pharmaceutical research |
PublicationTitleAlternate | Pharm Res |
PublicationYear | 1999 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
SSID | ssj0008194 |
Score | 1.6917957 |
Snippet | The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is... PURPOSEThe in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator,... |
SourceID | proquest pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 434 |
SubjectTerms | Administration, Oral Animals Biological and medical sciences Caco-2 Cells Callithrix Carbon Radioisotopes General and cellular metabolism. Vitamins Humans In Vitro Techniques Intestinal Absorption Iron Chelating Agents - chemistry Iron Chelating Agents - pharmacokinetics Jejunum - metabolism Male Mannitol - metabolism Medical sciences Perfusion Permeability Pharmacology. Drug treatments Pyridines - chemistry Pyridines - pharmacokinetics Rats Rats, Inbred F344 |
Title | In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator : Correlation with physico-chemical properties and oral activity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10213376 https://www.proquest.com/docview/222698204 https://search.proquest.com/docview/69707183 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELXo9oKEEN8spWUOqL00Iokde8MFlVWrLYcS0RbtbWXHjthLEpLsIb-Gv8pMnN0VSHCMooysjD3zxn5-w9h7oYpU20FP24SBUCIJtMt1IIzQDsMhqekQ2-JGLu7Fl2WyHLk57Uir3MbEIVDbKqc98g-Yx2SK6Up8qn8G1DSKDlfHDhoH7DDGQiGcsMPPlzfZt10oxnQ36EepWOCyF9Ff2j4Rln-SpiUJND-qdYu_pfD9LP4NOIfEc_WEPR4RI1x4Fz9lD1z5jJ1mXnK6P4e7_Q2q9hxOIduLUffP2a_rEr6vu6YCXVrAh9t1t4EM47HzCt09VAVoOLulytiCl6Emb53BordEcqn7Zo0ZriodfG1wJNdNVcL8B7HoquYjzKm_h2fUAe3qwkAqzatgq0UAGW34N6TcOgxiMHKR-7YVL9j91eXdfBGMTRmCOpa8C_iACVJp8pkRznGXqNBJnpswsqErhAxtVNDp8CxPpDGGy9C5ODQk9ZoUCN5esgmN-DWDQvAZwh9jVKSF4oVOotwKK12Smlg7O2XHf_hkVXsBjlWkOBaKfMqOtj5ajSuvXe3myZS9273FJUPnILp01aZdyVQhsKLvX3nH7g0j4uEYct_81_IRe-jFG4iJ9pZNumbjjhGadOaEHailOhmn4W-M3eZd |
link.rule.ids | 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,74079,74636 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pb9MwFLZgHEBCiN90Y-wd0HZZRFI7dsMFTRVTC2NUWod6i-zYEb0kWZIe8tfwr_JenLYCCY5VVMvKs9_7nv3l-xh7L1SeaNvraZswEErEgXaZDoQR2mE6JDUdYltcy9mt-LKKVwM3pxlolduc2CdqW2Z0Rv4B65hMsFyJT9VdQKZRdLk6OGjcZw9IhosMDNRq129RsevVo9RY4KYX0V_KPhE2f5IWJckzP650gy8l924W_4abfdm5fMqeDHgRLnyAn7F7rnjOThdecLo7h-X--6nmHE5hsZei7l6wX_MCfqzbugRdWMAfN-t2AwvMxs7rc3dQ5qDh7Ib6YgtehJpidQazzhLFperqNda3snDwvcaZzOuygOlP4tCV9UeYkruH59MBnelCTynNymCrRAALOu6vSbe1n0Q_yEXmTStestvLz8vpLBgsGYJqLHkb8B4RJNJkEyOc4y5WoZM8M2FkQ5cLGdoop7vhSRZLYwyXoXPj0JDQa5wjdHvFDmjGbxjkgk8Q_BijIi0Uz3UcZVZY6eLEjLWzI3b8R0zSystvpJHi2CbyETvaxigd9l2T7lbJiJ3snuKGoVsQXbhy06QyUQir6P-vfWD3AyPe4ZhwD_878gl7OFt-u0qv5tdfj9gjL-NAnLS37KCtN-4YQUpr3vVL8Tc84OcB |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgSAgJIX7TjbF7QNvLoiW1Yze8oKlQtYBGpW2ob5EdO6IvSZakD_lr-Fe5i9NWIMFjFMWycue77-zP3zH2Xqg80bbX0zZhIJSIA-0yHQgjtMNwSGo6xLa4kvNb8WUVrwZJoWagVW5jYh-obZnRHvkF5jGZYLoSF_nAilh-mn2s7gJqIEUHrUM3jfvsgcIihRxcrXa1FyW-XklKjQUGABH9pfITYSEoyUFJqvlxpRv8QbnvbPFv6NmnoNlT9mTAjnDpjf2M3XPFc3a69OLT3Tnc7O9SNedwCsu9LHX3gv1aFPBj3dYl6MICPlyv2w0sMTI7r9XdQZmDhrNrqpEteEFqstsZzDtLdJeqq9eY68rCwfcaZ7KoywKmP4lPV9YfYEqdPjy3Dmh_F3p6aVYGW1UCWNLWf00arv0k-kEuM9_A4iW7nX2-mc6DoT1DUI0lbwPeo4NEmmxihHPcxSp0kmcmjGzociFDG-V0TjzJYmmM4TJ0bhwaEn2Nc4Rxr9gBzfgNg1zwCQIhY1SkheK5jqPMCitdnJixdnbEjv-wSVp5KY40UhxLRj5iR1sbpcMabNKdx4zYye4tLh46EdGFKzdNKhOFEIu-f-0Nux8YsQ_H4Hv435FP2EP0wvTb4urrEXvkFR2InvaWHbT1xh0jXmnNu94TfwP6pOs_ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+and+in+situ+permeability+of+a+%27second+generation%27+hydroxypyridinone+oral+iron+chelator%3A+correlation+with+physico-chemical+properties+and+oral+activity&rft.jtitle=Pharmaceutical+research&rft.au=Lowther%2C+N&rft.au=Fox%2C+R&rft.au=Faller%2C+B&rft.au=Nick%2C+H&rft.date=1999-03-01&rft.issn=0724-8741&rft.volume=16&rft.issue=3&rft.spage=434&rft_id=info:doi/10.1023%2FA%3A1018886005136&rft_id=info%3Apmid%2F10213376&rft.externalDocID=10213376 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon |